Deep Learning-Based Classification of Temporal Stages of AT8-Labeled Tau Pathology After Experimental Traumatic Brain...

Tauopathies are characterised by a progressive accumulation of hyperphosphorylated tau. However, early and intermediate stages remain challenging to quantify due to subtle and heterogeneous morphological characteristics. This study evaluates a deep learning framework for classifying multiple temporal stages of tauopathy progression using AT8 (anti-phospho-tau antibody)-stained cortical micrographs in a controlled traumatic brain injury mouse model - an underexplored application. Three convolutional neural network (CNN) architectures were examined: a custom CNN and two transfer-learning models (InceptionV3 and DenseNet). Images were grouped into four post-injury stages: 1 day, 1 week, 1 month and 3 months. Preprocessing included normalisation, augmentation and oversampling to address imbalance. Performance was assessed using stratified k-fold cross-validation with accuracy, macro-F1, per-class F1, and one-vs-rest area under the receiver operating characteristic curve (AUC). DenseNet achieved the best overall performance (accuracy = 70.9%, macro-F1 = 0.68) with strong discrimination for the 1-week stage (F1 = 0.95). All models showed limited separability in the earliest post-injury stage (1 day), while intermediate to late stages (1-3 months) exhibited partial overlap, consistent with the progressive nature of tau accumulation. These results indicate that deep learning, particularly transfer learning, offers a scalable approach for automated temporal staging of tauopathy in preclinical histology. Although the results are based on internal cross-validation without independent animal-level identifiers or external cohorts, the proposed framework provides a reliable foundation for incorporating CNN-based analysis into digital neuropathology workflows. Larger multi-centre datasets and slide-level modelling will be required to assess generalisation and support applications in early detection, longitudinal tracking, and treatment evaluation of tau-related neurodegeneration.